scholarly journals 7Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis

2022 ◽  
pp. 103524
Author(s):  
Recai Türkoğlu ◽  
Nesrin Baliç ◽  
Tuğçe Kızılay ◽  
Ruziye Erol ◽  
Ece Akbayır ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Antibody Response ◽  
Spike Protein ◽  
Inactivated Vaccine

scholarly journals Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1140
Author(s):  
Yves Michiels ◽  
Nadhira Houhou-Fidouh ◽  
Gilles Collin ◽  
Jérôme Berger ◽  
Evelyne Kohli
Keyword(s):  
Multiple Sclerosis ◽  
Immune Responses ◽  
Antibody Response ◽  
Viral Vector ◽  
Humoral Response ◽  
Neutralizing Antibody ◽  
Protein S ◽  
Spike Protein ◽  
Vaccination Regimen ◽  
The Past

Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol.

scholarly journals Immunological imprinting of the antibody response in COVID-19 patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Teresa Aydillo ◽  
Alexander Rombauts ◽  
Daniel Stadlbauer ◽  
Sadaf Aslam ◽  
Gabriela Abelenda-Alonso ◽  
...  
Keyword(s):  
Immune Response ◽  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Humoral Immune Response ◽  
Nucleocapsid Protein ◽  
Spike Protein ◽  
Ongoing Research ◽  
Variable Regions ◽  
Humoral Immune ◽  
Human Coronaviruses

AbstractIn addition to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans are also susceptible to six other coronaviruses, for which consecutive exposures to antigenically related and divergent seasonal coronaviruses are frequent. Despite the prevalence of COVID-19 pandemic and ongoing research, the nature of the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Here we longitudinally profile the early humoral immune response against SARS-CoV-2 in hospitalized coronavirus disease 2019 (COVID-19) patients and quantify levels of pre-existing immunity to OC43, HKU1 and 229E seasonal coronaviruses, and find a strong back-boosting effect to conserved but not variable regions of OC43 and HKU1 betacoronaviruses spike protein. However, such antibody memory boost to human coronaviruses negatively correlates with the induction of IgG and IgM against SARS-CoV-2 spike and nucleocapsid protein. Our findings thus provide evidence of immunological imprinting by previous seasonal coronavirus infections that can potentially modulate the antibody profile to SARS-CoV-2 infection.

scholarly journals Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis

2012 ◽  
Vol 19 (7) ◽  
pp. 891-895 ◽  
Author(s):  
Emmanuelle Waubant ◽  
Ellen M Mowry ◽  
Lauren Krupp ◽  
Tanuja Chitnis ◽  
E Ann Yeh ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Antibody Response ◽  
Human Leukocyte Antigen ◽  
Human Leukocyte ◽  
Humoral Response ◽  
Nuclear Antigen ◽  
Leukocyte Antigen ◽  
Epstein Barr ◽  
Humoral Responses ◽  
Hsv 1

Background: As remote infections with common herpes viruses are associated with modulation of the risk of multiple sclerosis (MS), we hypothesized that antibody concentrations against these viruses may further modify risk. As many common viruses are first encountered during childhood, pediatric MS offer a unique opportunity to investigate more closely their influence on susceptibility. Our aim was to determine if MS patients who were positive for these viruses had higher levels of antibodies to these viruses. We also assessed whether human leukocyte antigen (HLA)-DRB1*1501 genotype influenced viral antibody levels. Methods: Antibody response levels toward Epstein Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV)-1, and HLA-DRB1*1501 status were determined in pediatric MS patients ( n=189) and controls ( n=38). Multivariate analyses were used, adjusted for age, gender, race, ethnicity and use of disease-modifying therapies. Results: The antibody concentrations against EBV (Epstein-Barr nuclear antigen 1 (EBNA-1), viral capsid antigen (VCA) and early antigen (EA)), CMV and HSV-1 were similar between pediatric MS patients and controls positive for seroconversion against the virus of interest. EBNA-1 humoral responses were higher in HLA-DRB1 positive individuals ( p=0.005) whereas other viral humoral responses were similar in HLA-DRB1 positive and negative individuals. Conclusion: Among those positive for EBNA-1, MS patients did not have higher levels of antibody response to EBNA-1: however, titers for EBNA-1 were higher in those who were HLA-DRB1 positive. This suggests that genotype might influence the humoral response to EBV. Whether other genotypes influence antibody response to other viruses remains to be determined.

scholarly journals Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1478
Author(s):  
Davide Firinu ◽  
Andrea Perra ◽  
Marcello Campagna ◽  
Roberto Littera ◽  
Federico Meloni ◽  
...  
Keyword(s):  
Observational Study ◽  
Antibody Response ◽  
Messenger Rna ◽  
Healthy Subjects ◽  
Booster Dose ◽  
Spike Protein ◽  
National Guidelines ◽  
Vector Vaccine ◽  
Boost Vaccination ◽  
Serum Igg

In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19. Methods: healthy subjects naïve for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (TFULL) and 15 (T15W) weeks after booster dose. Results: The median IgG anti-S-RBD levels at TFULL of Chad/BNT group were significantly higher than the BNT/BNT group and ChAd/ChAd. Those of BNT/BNT group were significantly higher than ChAd/ChAd. IgG anti-S-RBD of BNT1dose/CoV2 group were similar to BNT/BNT, ChAd/BNT and ChAd/Chad group. The levels among COVID-19 convalescents were significantly lower than ChAd/BNT, BNT/BNT, ChAd/Chad and BNT1dose/CoV2. The proportion of subjects reaching an anti-S-RBD titer >75 AU/mL, correlated with high neutralizing titer, was 94% in ChAd/BNT and BNT/BNT, 60% in BNT1dose/CoV2, 25% in ChAd/ChAd and 4.2% in convalescents. At T15W the titer of ChAd/BNT was still significantly higher than other vaccine schedules, while the anti-S-RBD decline was reduced for ChAd/ChAd and similar for other combinations. Conclusion: Our data highlight the magnitude of IgG anti-S-RBD response in ChAd/BNT dosing, supporting the current national guidelines for heterologous boosting

Anti-MOG antibody response in multiple sclerosis: A first step towards an immunopathological subtype of MS?

1998 ◽  
Vol 90 (1) ◽  
pp. 71
Author(s):  
R. Egg ◽  
M. Reindl ◽  
E. Dilitz ◽  
F. Deisenhammer ◽  
T. Berger
Keyword(s):  
Multiple Sclerosis ◽  
Antibody Response

Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD

2020 ◽  
Vol 338 ◽  
pp. 577110 ◽  
Author(s):  
Giannina Arru ◽  
Elia Sechi ◽  
Sara Mariotto ◽  
Ignazio R. Zarbo ◽  
Sergio Ferrari ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Antibody Response

scholarly journals Intradermal versus subcutaneous immunization with typhoid vaccine

1980 ◽  
Vol 84 (1) ◽  
pp. 11-16 ◽  
Author(s):  
S. Iwarson ◽  
P. Larsson
Keyword(s):  
Antibody Response ◽  
Adverse Reactions ◽  
Serum Antibody ◽  
Inactivated Vaccine ◽  
Typhoid Vaccine ◽  
Serum Antibody Response ◽  
Indirect Hemagglutination ◽  
Subcutaneous Immunization ◽  
Travel Abroad

SUMMARYSwedish nationals about to travel abroad were immunized against typhoid with a monovalent heat-inactivated vaccine which was administered intra- or subcutaneously. No major differences in serum antibody response were noted in the two groups of vaccinees as determined with direct agglutination and indirect hemagglutination techniques. As the intracutaneous route caused fewer adverse reactions this way of administration seems to be preferable.

Sign in / Sign up

Export Citation Format

Share Document